Zonagen (NASDAQ:ZONA)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Zonagen Charts. Click Here for more Zonagen Charts.](/p.php?pid=staticchart&s=N%5EZONA&p=8&t=15)
Zonagen, Inc. (NasdaqSC: ZONA) will present at the
following forum:
What: Informed Investors Biotechnology / Healthcare /
Pharmaceutical Investor Forum
When: June 15, 2005 @ 2:35 PM Eastern Time
Sponsors: Barron's, The Wall Street Journal, The American Stock
Exchange and Business Wire
Keynote Presentations: Lynn Sutherland, M.S., M.B.A. - President,
Sutherland Consulting
Dr. Navdeep Jaikaria, Senior Biotechnology Analyst, Rodman &
Renshaw, LLC
Where: The Princeton Club of New York, 15 West 43rd Street., New
York City, NY 10036
How to attend: Pre-registration is necessary. To register, contact
Cary Loeser, cloeser@wilink.com, or 804-327-3407. You may also call
Customer Service at 888-301-6618, or register at the following link:
http://www.informedinvestors.com/CustomEvent/89559/index.asp
If you are unable to attend the live event, the forum will be
available via webcast at
http://www.informedinvestors.com/CustomEvent/89559/index.asp
Contact: Louis Ploth, Jr., lploth@zonagen.com , 281-719-3454
Zonagen is a clinical-stage biopharmaceutical company focused on
the development of new, orally administered, small molecule drugs to
treat hormonal and reproductive system disorders. The Company's two
main products are Progenta(TM) for the treatment of adverse symptoms
associated with uterine fibroids and endometriosis and Androxal(TM)
for the treatment of testosterone deficiency. The Company intends to
begin a U.S. Phase III clinical trial for Androxal by year end 2005.
The Company believes it has sufficient data from its completed Phase
lb trial for the treatment of uterine fibroids to adequately select
dose for an advanced U.S. Phase II trial which is anticipated to begin
by year end 2005. The Company hopes that this Phase II trial may meet
the requirements to be the first pivotal trial of two required pivotal
trials. In addition, the Company intends to initiate a European Phase
II trial for the treatment of endometriosis by year end 2005.
Senior management of the Company has extensive experience in
product clinical development through the NDA process as well as
experience securing partnerships with major pharmaceutical companies.
In order to keep the burn rate to a minimum, the Company operates
as a near-virtual company, outsourcing the majority of tasks
associated with their development programs, including all preclinical
and clinical research and development. www.zonagen.com